Shattuck Labs, Inc. Common Stock (STTK)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 40
- Market Cap
- $687M
About Shattuck Labs, Inc. Common Stock
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
SentiSense also tracks daily options readings for Shattuck Labs, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Shattuck Labs, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.